Trial Profile

A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors MEETCD8-001

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BIS 2 (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man
Acronyms MEETCD8-001
Sponsors L and L Biopharma

04 Jun 2024 Results (n=30; As of January 5, 2024) assessing the safety, tolerability, pharmacokinetics and immunogenicity of LB4330 in patients with advanced solid tumors, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
11 Mar 2024 Planned primary completion date changed from 1 Sep 2026 to 1 Sep 2025.
06 Jun 2023 Study design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com